Video

ecancer's extensive video archive features interviews, panel discussions and conference coverage on almost every topic in oncology.

ASH 2022: Multiple myeloma roundup

Dr Thomas Martin - UCSF Medical Centre, San Francisco, USA
ASH 2022: Multiple myeloma roundup ( Dr Thomas Martin - UCSF Medical Centre, San Francisco, USA )
22 Dec 2022

Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk cytogenetic AML

Dr Eunice Wang - Roswell Park Comprehensive Cancer Center, New York, USA
Gemtuzumab ozogamicin plus chemotherapy improves outcomes in intermediate-risk cytogenetic AML ( Dr Eunice Wang - Roswell Park Comprehensive Cancer Center, New York, USA )
22 Dec 2022

Breast cancer patients who interrupted endocrine therapy to pursue pregnancy did not have worse short-term recurrence rates

Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain
Breast cancer patients who interrupted endocrine therapy to pursue pregnancy did not have worse short-term recurrence rates ( Dr Cristina Saura - Vall d’Hebron University Hospital, Barcelona, Spain )
22 Dec 2022

Interruption of endocrine therapy in young breast cancer patients does not increase the risk of short-term relapse

Dr Ann Partridge - Dana-Farber Cancer Institute, Boston, USA
Interruption of endocrine therapy in young breast cancer patients does not increase the risk of short-term relapse ( Dr Ann Partridge - Dana-Farber Cancer Institute, Boston, USA )
21 Dec 2022

Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL

Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA
Zanubrutinib demonstrates superior PFS compared with ibrutinib for treatment of R/R CLL and SLL ( Dr Mazyar Shadman - Fred Hutchinson Cancer Center, Seattle, USA )
21 Dec 2022

Effective treatment of low risk acute GVHD with itacitinib monotherapy

Prof Aaron Etra - The Tisch Cancer Institute, Mount Sinai, USA
Effective treatment of low risk acute GVHD with itacitinib monotherapy ( Prof Aaron Etra - The Tisch Cancer Institute, Mount Sinai, USA )
21 Dec 2022

Maximising cancer treatment and research through omics, data sharing, and open science

Dr Simon Parker - Data protection co-ordinator at the German Human Genome-phenome Archive
Maximising cancer treatment and research through omics, data sharing, and open science ( Dr Simon Parker - Data protection co-ordinator at the German Human Genome-phenome Archive )
20 Dec 2022

Epidemiology, detection, and management of NAFLD: a Latin American perspective

Dr Nahum Mendez-Sanchez - National Autonomous University of Mexico, Mexico City, Mexico
Epidemiology, detection, and management of NAFLD: a Latin American perspective ( Dr Nahum Mendez-Sanchez - National Autonomous University of Mexico, Mexico City, Mexico )
20 Dec 2022

Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R multiple myeloma

Dr Ajai Chari - Mount Sinai School of Medicine, New York, USA
Talquetamab: Robust efficacy and manageable safety for heavily pretreated R/R multiple myeloma ( Dr Ajai Chari - Mount Sinai School of Medicine, New York, USA )
20 Dec 2022

What is required to advance data ethics, data sharing, and Open Science across LMICs

Dr Priya Kumari - Regional Cancer Centre Trivandrum, Trivandrum, India
What is required to advance data ethics, data sharing, and Open Science across LMICs ( Dr Priya Kumari - Regional Cancer Centre Trivandrum, Trivandrum, India )
20 Dec 2022

Zanubrutinib improves PFS compared to ibrutinib for R/R chronic lymphocytic leukaemia and small lymphocytic lymphoma

Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA
Zanubrutinib improves PFS compared to ibrutinib for R/R chronic lymphocytic leukaemia and small lymphocytic lymphoma ( Dr Jennifer Brown - Dana-Farber Cancer Institute, Boston, USA )
19 Dec 2022

A genomic assay may predict long-term prognosis in premenopausal patients with HR+ early-stage breast cancer

Dr Ruth O'Regan - University of Rochester, Rochester, USA
A genomic assay may predict long-term prognosis in premenopausal patients with HR+ early-stage breast cancer ( Dr Ruth O'Regan - University of Rochester, Rochester, USA )
19 Dec 2022